Navigation Links
CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas' Tender Offer
Date:2/27/2009

PALO ALTO, Calif., Feb. 27 /PRNewswire-FirstCall/ -- CV Therapeutics, Inc. (Nasdaq: CVTX) today advised its stockholders to take no action at this time in response to Astellas Pharma Inc.'s announcement that its indirect subsidiary, Sturgeon Acquisition, Inc., has commenced an unsolicited tender offer for all outstanding common shares of CV Therapeutics at a price of $16.00 per share in cash.

CV Therapeutics' board of directors, in consultation with its independent financial and legal advisors, intends to advise stockholders of its formal position regarding the offer within 10 business days by filing a solicitation/recommendation statement on Schedule 14D-9 with the Securities and Exchange Commission and made available to stockholders.

Barclays Capital and Goldman Sachs are serving as financial advisors, and Latham & Watkins LLP is serving as legal counsel, to CV Therapeutics.

About CV Therapeutics

CV Therapeutics, Inc., headquartered in Palo Alto, California, is a biopharmaceutical company primarily focused on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. CV Therapeutics Europe Ltd. is the company's European subsidiary based in the United Kingdom.

CV Therapeutics' approved products in the United States include Ranexa(R) (ranolazine extended-release tablets), indicated for the treatment of chronic angina, and Lexiscan(R) (regadenoson) injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. Ranexa(R) (ranolazine prolonged-release tablets) is approved for use in the European Union as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who a
'/>"/>

SOURCE CV Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 17, 2014 The Pistoia Alliance, ... lowering the barriers to innovation in life sciences ... of Carmen Nitsche as Executive Director Business Development ... its global reach. , Carmen joins the Pistoia ... Corporate Development. At Accelrys, she managed various life ...
(Date:9/16/2014)... This report analyzes the worldwide markets for Bioinformatics ... and Biocontent. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... World. Annual estimates and forecasts are provided for the period ... for these markets. Market data and analytics are derived from ...
(Date:9/16/2014)... D.C., September 16, 2014 --The emerging field of ... to the next level, enabling the construction of ... efficient devices, individual molecules would take on the ... transistors. , A team of researchers from five ... candidate for use in small-scale electronics: a molecule ...
(Date:9/16/2014)... BlueInGreen® , a water quality company offering ... gases into liquids, announced the addition of ... firm to its sales network. H2Flow will promote ... wastewater applications in the Canadian provinces of Ontario ... and serves Quebec and Ontario markets for water, ...
Breaking Biology Technology:Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2Global Bioinformatics Industry 2Global Bioinformatics Industry 3Global Bioinformatics Industry 4Global Bioinformatics Industry 5Global Bioinformatics Industry 6Global Bioinformatics Industry 7Global Bioinformatics Industry 8Global Bioinformatics Industry 9Global Bioinformatics Industry 10Global Bioinformatics Industry 11Global Bioinformatics Industry 12Global Bioinformatics Industry 13Global Bioinformatics Industry 14Global Bioinformatics Industry 15Global Bioinformatics Industry 16Global Bioinformatics Industry 17Global Bioinformatics Industry 18Global Bioinformatics Industry 19Global Bioinformatics Industry 20Global Bioinformatics Industry 21Global Bioinformatics Industry 22Global Bioinformatics Industry 23The future face of molecular electronics 2BlueInGreen® Expands into Canada – Signs Representative Agreement with H2Flow Equipment Inc. 2
... engine dedicated to recruiting exceptional talent to jobs at ... the most rewarding careers on the planet, but they ... StartUpHire website, www.startuphire.com , lists thousands of jobs ... investor, and more. Search agents allow users to ...
... (Pink Sheets: SYNJ), Reports that it has engaged in ... The job of the Director will be to coordinate ... Pinnacle Energy Division. The Company is currently considering ventures ... production, and microwave plasma physics. To that end, the ...
... NOVATO, Calif., March 18 BioMarin Pharmaceutical Inc. (Nasdaq: ... for clinical trial authorization (CTA) for BMN 110 or ... lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or ... Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA). BioMarin ...
Cached Biology Technology:StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 2StartUpHire Launches Comprehensive Search Engine for Jobs at Venture-Backed Companies 3Syndication Inc. Seeks 'DIRECTOR OF TECHNICAL ENGINEERING' for 'PINNACLE ENERGY' - Its New Alternative Energy Subsidiary 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 2BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 3BioMarin's Clinical Trial Application for GALNS for Morquio A Syndrome Accepted by the MHRA 4
(Date:9/16/2014)... such as buying clothing not made in a sweat ... their own bags when they go shopping? According to ... Research , ethical consumption is motivated by a need ... into action. , "Advocates of ethical consumerism suggest that ... the products they choose, but unfortunately only a small ...
(Date:9/16/2014)... Sept. 16, 2014  Cross Match Technologies, a ... announced today the launch of its Verifier ® ... identity of an individual using their secure credentials ... rapidly reads credential documents with embedded biometric data ... the biometric to a live scan of their ...
(Date:9/15/2014)... (September 15, 2014) The so-called central dogma ... proteinhas long provided a simplified explanation for how ... organisms. , In reality, of course, the ... first articulated nearly 60 years ago by Nobel ... structure. For one, there are multiple types of ...
Breaking Biology News(10 mins):Why are consumers willing to spend more money on ethical products? 2Cross Match Launches New Identity Management Handheld Solution 2Scientists discover RNA modifications in some unexpected places 2
... discovery by UNC scientists describes how cells infected by ... called exosomes, changing their cellular "cargo" of proteins and ... the growth of recipient cells from benign to cancer-producing. ... effects and potentially manipulate other cells throughout the body. ...
... University of California, San Diego School of Medicine and ... approved drugs to more than 1,000 proteins in Mycobacterium ... avenues to repurpose these drugs to treat TB. ... Computational Biology . "Tuberculosis is currently one of ...
... study by researchers at the Johns Hopkins Bloomberg School of ... disease among male clients of the commercial sex industry in ... drug use as the primary transmission mode of all HIV ... of publication in the journal Sexually Transmitted Infections . ...
Cached Biology News:UNC scientists identify cellular communicators for cancer virus 2TB-drugome provides new targets for anti-tuberculosis drug discovery 2Study examines risk of heterosexual HIV transmission in China 2